Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 28, 2016

Janssen begins Phase IIb study of drug combination to treat hepatitis C virus infection

Janssen Research & Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.

Janssen Research & Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.

Simeprevir (Olysio) is a macrocyclic compound that non-covalently fuses with and inhibits a NS3/4A hepatitis C virus (HCV) protease, which is considered responsible for cleaving and processing the HCV-encoded polyprotein.

Developed by Achillion Pharmaceuticals, odalasvir (ACH 3102) is an orally administered, pan-genotypic, second-generation hepatitis C virus (HCV) NS5A inhibitor.

AL-335, also known as JNJ-4178, is a novel uridine nucleotide analog.

"The Phase IIb study is being undertaken as a global, multi-centre study across sites in North America, Europe and Asia, and is a part of Janssen’s global development programme for JNJ-4178."

The Phase IIb study is being undertaken as a global, multi-centre study across sites in North America, Europe and Asia, and is a part of Janssen’s global development programme for JNJ-4178.

The study is intended to evaluate the efficacy and safety, as well as determine the pharmacokinetics profile of the JNJ-4178 / AL-335, odalasvir and simeprevir while examining treatment-naive and treatment-experienced non-cirrhotic patients with chronic hepatitis C virus genotype 1, 2, 4, 5, and 6 infection.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

It is primarily focused on achieving the percentage of patients with a sustained virological response induced by the drug combination post-treatment.

During the study, the patients will be administered with the triple combination for either six or eight weeks.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU